MYOS RENS Technology Inc. focuses on the discovery, development, and commercialization of nutritional ingredients, functional foods, and other technologies that enhance muscle health and performance. More Details
Imperfect balance sheet with weak fundamentals.
Share Price & News
How has MYOS RENS Technology's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MYOS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: MYOS's weekly volatility has decreased from 29% to 7% over the past year.
7 Day Return
US Personal Products
1 Year Return
US Personal Products
Return vs Industry: MYOS underperformed the US Personal Products industry which returned 18.1% over the past year.
Return vs Market: MYOS underperformed the US Market which returned 19.1% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is MYOS RENS Technology's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StWhat Does MYOS RENS Technology's (NASDAQ:MYOS) CEO Pay Reveal?
3 months ago | Simply Wall StAre Insiders Buying MYOS RENS Technology Inc. (NASDAQ:MYOS) Stock?
5 months ago | Simply Wall StHow Much Does MYOS RENS Technology's (NASDAQ:MYOS) CEO Make?
Is MYOS RENS Technology undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate MYOS's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate MYOS's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: MYOS is unprofitable, so we can't compare its PE Ratio to the US Personal Products industry average.
PE vs Market: MYOS is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MYOS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MYOS is overvalued based on its PB Ratio (5.9x) compared to the US Personal Products industry average (1.8x).
How is MYOS RENS Technology forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Household industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as MYOS RENS Technology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Take a look at our analysis of MYOS’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- Explore growth companies in the Household industry.
How has MYOS RENS Technology performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MYOS is currently unprofitable.
Growing Profit Margin: MYOS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MYOS is unprofitable, but has reduced losses over the past 5 years at a rate of 7.9% per year.
Accelerating Growth: Unable to compare MYOS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MYOS is unprofitable, making it difficult to compare its past year earnings growth to the Personal Products industry (28.5%).
Return on Equity
High ROE: MYOS has a negative Return on Equity (-179.97%), as it is currently unprofitable.
How is MYOS RENS Technology's financial position?
Financial Position Analysis
Short Term Liabilities: MYOS's short term assets ($2.3M) exceed its short term liabilities ($854.0K).
Long Term Liabilities: MYOS's short term assets ($2.3M) exceed its long term liabilities ($405.0K).
Debt to Equity History and Analysis
Debt Level: MYOS's debt to equity ratio (48%) is considered high.
Reducing Debt: MYOS's debt to equity ratio has increased from 6.7% to 48% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MYOS has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: MYOS has less than a year of cash runway if free cash flow continues to grow at historical rates of 8.6% each year.
What is MYOS RENS Technology current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MYOS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MYOS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MYOS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MYOS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MYOS's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Joe Mannello (62 yo)
Mr. Joseph Mannello, also Known as Joe, has been the Chief Executive Officer of MYOS RENS Technology Inc. since August 24, 2017 and served as its Interim Chief Executive Officer from September 1, 2016 to A...
CEO Compensation Analysis
Compensation vs Market: Joe's total compensation ($USD83.36K) is below average for companies of similar size in the US market ($USD564.51K).
Compensation vs Earnings: Joe's compensation has been consistent with company performance over the past year.
|CEO & Director||3.25yrs||US$83.36k||12.86% |
|Controller||4.17yrs||no data||no data|
|Chief Technology Officer||no data||no data||no data|
|Head of Marketing||2.83yrs||no data||no data|
|Chief Strategist||1.25yrs||no data||no data|
Experienced Management: MYOS's management team is considered experienced (3 years average tenure).
|CEO & Director||3.25yrs||US$83.36k||12.86% |
|Independent Director||4.25yrs||US$50.00k||0.99% |
|Independent Chairman of Board & Chairman of the Scientific Advisory Board||8.58yrs||US$4.00k||2.34% |
|Independent Director||6.75yrs||US$55.00k||3.19% |
|Independent Director||1.25yrs||US$8.00k||2.7% |
|Independent Director & Member of Scientific Advisory Board||9.33yrs||US$36.00k||0.66% |
|Member of Scientific Advisory Board||7.75yrs||no data||no data|
|Member of Scientific Advisory Board||8.92yrs||no data||no data|
|Independent Director||1.92yrs||US$20.00k||0.14% |
Experienced Board: MYOS's board of directors are considered experienced (5.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 32.9%.
MYOS RENS Technology Inc.'s company bio, employee growth, exchange listings and data sources
- Name: MYOS RENS Technology Inc.
- Ticker: MYOS
- Exchange: NasdaqCM
- Founded: 2007
- Industry: Personal Products
- Sector: Household
- Market Cap: US$12.314m
- Shares outstanding: 12.19m
- Website: https://www.myosrens.com
Number of Employees
- MYOS RENS Technology Inc.
- 45 Horsehill Road
- Suite 106
- Cedar Knolls
- New Jersey
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|MYOS||NasdaqCM (Nasdaq Capital Market)||Yes||Common Stock||US||USD||Sep 2008|
|73M||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Sep 2008|
MYOS RENS Technology Inc. focuses on the discovery, development, and commercialization of nutritional ingredients, functional foods, and other technologies that enhance muscle health and performance. The c...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/11/18 23:50|
|End of Day Share Price||2020/11/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.